All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy
MediCom Oncology Clinical Pearls Podcasts
4 minutes
7 years ago
New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
